AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11001109
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (7VPnC) combined with Haemophilus influenzae type b vaccine (HbOC)
Trial: 11001109
Drug: Routine vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine vaccines only (control group)
Trial: 6705277
Drug: 3 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of 1 ml (Group I)
Trial: 6705277
Drug: 3 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 injections of 2 ml (Group II)
Trial: 6705277
Drug: 4 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 injections of 1 ml (Group III)
Trial: 30126781
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure therapy (Prevena)
Trial: 9531078
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy followed by simultaneous resection of primary and metastatic lesions (when feasible) and further chemotherapy
Trial: 9531078
Drug: Simultaneous surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous surgical treatment of primary and metastatic tumor
Trial: 9531078
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment including chemotherapy and surgery
Trial: 1092576
Drug: Attenuated influenza
RxNorm normalized name: Live attenuated influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated influenza virus vaccine (ANN strain)
Trial: 25008799
Drug: Naso-gastric infusion
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naso-gastric infusion of 500mL/0kJ water (Stomach distention)
Trial: 25008799
Drug: Naso-gastric infusion
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naso-gastric infusion of 500mL/1770kJ chocolate milk (Stomach distention with caloric content)
Trial: 25008799
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 500mL/1770kJ chocolate milk (Stomach distention with caloric content and oral exposure)
Trial: 15705690
Drug: Rectal artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal artemether
Trial: 10368486
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of instruments (vacuum first, then forceps, or vice versa)
Trial: 8888321
Drug: 2.5-mg silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-mg silver acetate lozenge
Trial: 2058340
Drug: Latamoxef 2
RxNorm normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Latamoxef 2 g single-dose prophylaxis
Trial: 20595283
Drug: Injection therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection therapies
Trial: 20595283
Drug: Drug-based intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-based intervention
Trial: 15923248
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with salmeterol and fluticasone propionate (SFC)
Trial: 11864664
Drug: Soy isoflavone
RxNorm normalized name: soy isoflavone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavone 100 mg daily for 4 months
Trial: 7566021
Drug: Margarine containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Margarine containing sitostanol ester (1.8 or 2.6 g of sitostanol per day)
Trial: 2090399
Drug: Bendazac lysine
RxNorm normalized name: bendazac lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendazac lysine (anti-cataract drug)
Trial: 28024935
Drug: Nitrate (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate (140 mL·day−1 NO3−‐rich beetroot juice, 8.4 mmol NO3−·day−1)
Trial: 28024935
Drug: Nitrate +
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate + Iodide (140 mL·day−1 NO3−‐rich beetroot juice and 450 μg potassium iodide·day−1)
Trial: 19363857
Drug: 0.1% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tretinoin gel
Trial: 16709386
Drug: Levosimendan (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (loading dose of 12 microg/kg followed by 24-hour infusion of 0.2 microg/kg per min)
Trial: 16709386
Drug: Dobutamine (24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (24-hour infusion of 7.5 microg/kg per min)
Trial: 11776446
Drug: 4.0 J/cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 J/cm2 treatment group
Trial: 11776446
Drug: 1.7 J/cm2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 J/cm2 treatment group
Trial: 9621294
Drug: OTZ (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTZ (0.5 g three times a day orally with meals)
Trial: 31560066
Drug: Apalutamide (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide (240 mg daily)
Trial: 29198449
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg once daily for 14 days
Trial: 29198449
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive alone (reference)
Trial: 15266201
Drug: Innovative research
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovative research designs and psychosocial treatments
Trial: 9357184
Drug: Metronidazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (400 mg tid for 10 days, followed by placebo for 50 days)
Trial: 9357184
Drug: Isapghul (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isapghul (10 g bid for 60 days)
Trial: 9357184
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 capsule bid for 60 days)
Trial: 8479248
Drug: Cumulative fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative fraction absorbed‐time profile method of paracetamol
Trial: 8479248
Drug: Proportional area
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proportional area under the curve method of paracetamol
Trial: 3083092
Drug: Intravenous 1‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1‐mg dose of leuprolide
Trial: 3083092
Drug: Subcutaneous 1‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous 1‐mg dose of leuprolide
Trial: 3083092
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of intravenous and subcutaneous administration
Trial: 23316876
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) therapy
Trial: 23316876
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) therapy
Trial: 23316876
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) therapy
Trial: 18378313
Drug: Medication (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (n = 596)
Trial: 18378313
Drug: Topical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prostaglandin analogues (PGAs)
Trial: 9540780
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (INR 2.5)
Trial: 9540780
Drug: Subcutaneous calcium
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous calcium heparin 0.2 ml bid (8.00 and 20.00)
Trial: 9540780
Drug: Subcutaneous calcium
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous calcium heparin (0.5 ml at 20.00)
Trial: 8112905
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ST-depression and low maximal work load
Trial: 14658256
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without indomethacin
Trial: 8923361
Drug: Sulfasalazine (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (target dosage, 40 mg/kg/day)
Trial: 8923361
Drug: Auranofin (6‐9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin (6‐9 mg/day)
Trial: 1399378
Drug: Omeprazole, 40
RxNorm normalized name: Omeprazole, 40 mg oral delayed release capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 40 mg o.m., for 10 days
Trial: 3888030
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg sodium fluoride daily
Trial: 25523634
Drug: Weekly low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly low-dose methotrexate (MTX) as an add-on therapy
Trial: 17454467
Drug: Lidocaine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (10 ml 2% lidocaine) injected down the drain before removal
Trial: 14997327
Drug: Age-related increase
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-related increase in LEP(u/l)
Trial: 11361048
Drug: CS-866 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-866 (oral administration)
Trial: 11361048
Drug: RNH-6270 (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNH-6270 (intravenous administration)
Trial: 11361048
Drug: CS-866 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-866 (up to 160 mg/day)
Trial: 7803318
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (16 sessions over a six-month period)
Trial: 30916626
Drug: Penile traction
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penile traction therapy with RestoreX device for 30 to 90 minutes per day
Trial: 22237835
Drug: Gemcitabine 1
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1 g/m2 weekly on days 1, 8, and 15 (arm A)
Trial: 22237835
Drug: PEFG regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEFG regimen (cisplatin and epirubicin 40 mg/m2, day 1; gemcitabine 600 mg/m2, days 1, 8; 5-fluorouracil 200 mg/m2 daily, days 1-28) (arm B)
Trial: 17362049
Drug: Various immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various immunotherapy approaches (including dendritic cell vaccination, whole cell vaccines, and recombinant viral vectors)
Trial: 17362049
Drug: Chemotherapy (taxane-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (taxane- and platinum-compound-based)
Trial: 15894038
Drug: 2.5% glycyrrhetinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% glycyrrhetinic acid cream (n=9)
Trial: 15894038
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (n=9)
Trial: 12080401
Drug: Prototype beta‐glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype beta‐glucan cereal (8.1 g% beta‐glucan)
Trial: 12080401
Drug: Beta‐glucan bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐glucan bar (6.5 g% beta‐glucan)
Trial: 12080401
Drug: Commercial oat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial oat bran breakfast cereal (4.4 g% beta‐glucan)
Trial: 2019667
Drug: Etoposide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (600 mg/m2) + Cisplatin (100 mg/m2) administered intraperitoneally
Trial: 7078417
Drug: ZnSO4 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZnSO4 (100 mg/day Zn++)
Trial: 30821349
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 50-150 μg/kg/min (Group P)
Trial: 30821349
Drug: Dexmedetomidine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine bolus of 1 μg/kg followed by infusion at 0.5-1.0 μg/kg/hr (Group D)
Trial: 28673215
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (0.5 mg/kg pre‐incision, 0.25 mg/kg/hour intraoperatively, 0.1 mg/kg/hour for 24 hours)
Trial: 28673215
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion and Placebo
Trial: 25771141
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gel (GII)
Trial: 25771141
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (GIII, control group)
Trial: 21584666
Drug: Epirubicin 110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 110 mg/m(2) + Paclitaxel 200 mg/m(2) every 21 days (dose-escalated)
Trial: 21584666
Drug: Epirubicin 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 75 mg/m(2) + Paclitaxel 175 mg/m(2) every 10 days (dose-dense)
Trial: 26976659
Drug: Yoga in
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga in combination with standard treatment
Trial: 21166600
Drug: valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 160 mg once daily in the morning
Trial: 21166600
Drug: valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 160 mg once daily in the evening
Trial: 19877092
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi (60 minutes, 10 modified forms from classic Yang style, twice weekly for 12 weeks)
Trial: 11296615
Drug: Amifostine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (500 mg) administered on days carboplatin was given
Trial: 9290304
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for lymphoedema
Trial: 3103174
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.42% carbonated bupivacaine
Trial: 3103174
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml 0.5% bupivacaine hydrochloride
Trial: 22438072
Drug: Densulin® N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Densulin® N (NPH) plus Densulin® R (regular), 100 UI/ml
Trial: 22438072
Drug: InsulatardHM® (NPH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: InsulatardHM® (NPH) plus ActrapidHM®, 100 UI/ml
Trial: 12208797
Drug: 50 microg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg/d transdermal E2
Trial: 12208797
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d oral CEE
Trial: 12080685
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg in 10 ml solution
Trial: 12080685
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NS 10 ml)
Trial: 1773686
Drug: Patient activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient activation intervention (45-min intervention + 1-h self-administered booster)
Trial: 30488367
Drug: Combined immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunosuppressive treatment (CIST) including intravenous cyclophosphamide, mycophenolate mofetil, azathioprine, leflunomide, hydroxychloroquine, and glucocorticoids.
Trial: 30488367
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (CYC) alone with glucocorticoids.
Trial: 24842445
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg or 30 mg total dose)
Trial: 20032533
Drug: Ritonavir-boosted protease
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted protease inhibitors with rifampicin
Trial: 20032533
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose protease inhibitors with rifampicin
Trial: 11794812
Drug: New design
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New design of tablets with a hydrophilic matrix containing 300 mg of diltiazem
Trial: 11794812
Drug: Capsules containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing prolonged liberation microgranules of 300 mg of diltiazem (reference formulation)
Trial: 10189261
Drug: Carbatrol (CBTL)
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbatrol (CBTL) 400 mg b.i.d. for 5 days
Trial: 10189261
Drug: Tegretol-XR (TXR)
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tegretol-XR (TXR) 400 mg b.i.d. for 5 days
Trial: 24349363
Drug: S-1-based chemotherapy
RxNorm normalized name: menthol 1 MG [Luden's]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1-based chemotherapy
Trial: 24349363
Drug: Capecitabine-based chemotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine-based chemotherapy
Trial: 18349204
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcitonin (200 IE) and ketamine (0.4 mg/kg)
Trial: 18349204
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcitonin and ketamine
Trial: 17066247
Drug: MARB regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MARB regimen (metronidazole 250 mg tid + amoxicillin 500 mg qid + ranitidine 300 mg hs + bismuth 300 mg qid) for 14 days
Trial: 17066247
Drug: OCA regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCA regimen (omeprazole 40 mg bid + clarithromycin 500 mg bid + amoxicillin 1 g bid) for 14 days
Trial: 30681185
Drug: Teprenone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprenone (150 mg/day)
Trial: 15068414
Drug: H2-receptor antagonist
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonist (nizatidine, 300 mg/day)
Trial: 11302295
Drug: Psychosocial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial therapy (11 individual sessions including physiologic relaxation, cognitive behavioral therapy, and cardiovascular health education)
Trial: 11302295
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no psychosocial therapy)
Trial: 8507888
Drug: recombinant alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant alpha‐2a interferon at doses of 3MU intramuscularly thrice weekly for 6 months
Trial: 18250970
Drug: Whole-body cryotherapy
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cryotherapy (WBCT) - 15 daily visits, 2-3 minutes each at temperatures from -160°C to -110°C
Trial: 8886215
Drug: Naprelan 500
RxNorm normalized name: Naprelan 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naprelan 500 mg once daily
Trial: 8886215
Drug: Naprelan 1000
RxNorm normalized name: Naprelan
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naprelan 1000 mg once daily
Trial: 8886215
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg QID
Trial: 1793782
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral mesalazine four times daily (18 patients)
Trial: 1793782
Drug: Steroid enemas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid enemas twice daily (19 patients)
Trial: 30615259
Drug: Quadruple low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple low CNI regimen (everolimus target trough level 3-5 ng/mL, reduced CNI with tacrolimus 3-5 ng/mL or cyclosporine 25-75 ng/mL, cell cycle inhibitor, prednisone)
Trial: 30615259
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple CNI regimen (tacrolimus target trough level >5 ng/mL or cyclosporine >100 ng/mL, cell cycle inhibitor, prednisone)